Skip to content

Exhaled Breath Profile at altitude

Exhaled Breath Profile in Acute Mountain Sickness, a field study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26964
Enrollment
140
Registered
2013-07-09
Start date
2013-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Mountain Sickness (AMS), High Altitude Cerebral Edema (HACE) and High Altitude Pulmonary Edema (HAPE).

Interventions

None listed

Sponsors

Leiden University Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All subjects visiting the Capanna Regina Margherita (4554 m, Italy) willing and able to comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Use of inhalation steroids. 2. Use of inhalation beta-adrenergic agonists. 3. Use of acetazolamide. 4. A course of oral corticosteroids, antibiotics or a respiratory infection within 4 weeks prior to the study. 5. LLS &#8804; 3 of ESQc &#8804; 0,7 6. Age < 18 years

Design outcomes

Primary

MeasureTime frame
AMS breathprint generating study: a specific VOC breathprint of subjects with AMS, measured during a stay in the Capanna Regina Margherita, Italy, at an altitude of 4559 meter. Proof of concept study: A VOC breathprint of subjects with, or without AMS, measured during a stay in the Capanna Regina Margherita, Italy, at an altitude of 4559 meter.

Secondary

MeasureTime frame
Specific VOC breathprint which is associated with the development of HACE, as measured during a stay in the Capanna Regina Margherita, Italy, at an altitude of 4559 meter. Specific VOC breathprint which is associated with the development of HAPE, as measured during a stay in the Capanna Regina Margherita, Italy, at an altitude of 4559 meter. SGVAS score that is associated with AMS diagnosis (scored by LLSRS and the ESQc). SGVAS score that is associated with specific AMS VOCs breathprints. &#8722; Clinical measurements that are associated with AMS. &#8722; IGVAS score that is associated with AMS diagnosis (scored by LLSRS and the ESQc).

Contacts

Public ContactR.R. Berendsen

Dept. of Anesthesiology LUMC, P5-Q

r.r.berendsen@lumc.nl+31 (0)71 5262301

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)